Efficacy News and Research

RSS

New compound V-161 offers hope in the fight against antibiotic-resistant bacteria

V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.

23 Jan 2025

Multi-omics approach identifies potential drug combinations for AML treatment

Acute myeloid leukaemia (AML) is mainly characterized by an increase in the number of myeloid cells in the bone marrow and a decrease in mature cells, accounting for 28% of leukaemia cases, with a five-year survival rate of only 30.5%.

23 Jan 2025

New approach to treating ependymoma with leukemia drug

Rakesh Jain PhD, Director of the E.L. Steele Laboratories for Tumor Biology at Massachusetts General Hospital and A. Werk Cook Professor of Radiation Oncology at Harvard Medical School, is senior author of a new study in PNAS, Targeting EPHB2/ABL1 Restores Anti-Tumor Immunity in Preclinical Models of Ependymoma.

23 Jan 2025

Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and efficacy. While ischemic stroke rates were slightly higher, they were not statistically significant, warranting further phase 3 trials for confirmation.

23 Jan 2025

Metronomic chemotherapy offers hope for children with neuroblastoma

Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease.

23 Jan 2025

Prehabilitation associated with fewer complications and improved recovery after surgery

Actively preparing for major surgery by exercising and improving diet (known as "prehabilitation") is associated with fewer complications, less time in hospital, and improved recovery and quality of life in adults, finds an analysis of clinical trials published by The BMJ today.

23 Jan 2025

Prehabilitation may improve surgical recovery and reduce complications

A new study published in The BMJ suggests that prehabilitation (also called prehab) may be able to reduce complications and length of hospitalization after surgery, while also improving quality of life and physical recovery.

23 Jan 2025

Real-world effectiveness and safety of olaparib in HRD-positive BRCA wild-type ovarian cancer

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy.

23 Jan 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

Genomic insights and new treatment paradigms related to HER2-low breast cancer

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms."

22 Jan 2025

New air-liquid interface method enhances hair follicle formation in skin organoids

For decades, creating human skin models with physiological relevance has been a persistent challenge in dermatological research.

22 Jan 2025

Study identifies new molecular target for treating keloids

Keloids are fibrotic scars that extend beyond the boundaries of the original wound, often causing physical disfigurement and emotional distress.

22 Jan 2025

Diagnostic guidelines released for limbic-predominant age-related TDP-43 encephalopathy

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults.

22 Jan 2025

Single dose of novel drug shows tumor-clearing potential in breast cancer models

Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women.

22 Jan 2025

Green tea enriched films show promise for treating oral mucositis

Green tea shines as a natural powerhouse of antioxidants, with catechins leading the charge among its polyphenols, which protect cells from oxidative stress.

22 Jan 2025

Antidepressant fluoxetine found ineffective for early COVID-19 treatment

Findings reveal fluoxetine's weak antiviral effects in COVID-19, with no significant benefits in symptom resolution compared to other antiviral treatments.

22 Jan 2025

How gut microbiota impacts childhood obesity

Gut microbiota plays a critical role in childhood obesity by influencing energy metabolism, inflammation, and appetite regulation, with emerging therapeutic strategies like probiotics, dietary interventions, and fecal microbiota transplantation showing promise.

21 Jan 2025

SHEA calls for continued U.S. partnership with the World Health Organization

The Society for Healthcare Epidemiology of America (SHEA) wants to emphasize the importance of global partnerships in addressing health threats that impact all of us, as Americans and global citizens. We urge President Trump to reconsider the decision to terminate the U.S. relationship with the World Health Organization (WHO).

21 Jan 2025

Pregnant women often left out of drug trials, study finds

A new study by researchers from the Brown University School of Public Health found that pregnant women are regularly excluded from clinical drug trials that test for safety, raising concerns for the efficacy of these medications for maternal and child health.

21 Jan 2025

Azvudine beats paxlovid in reducing COVID-19 deaths

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed.

21 Jan 2025

Previous
1
...
93
94
95
96
97
98
99
...
1332
Next

Efficacy News and Research

New compound V-161 offers hope in the fight against antibiotic-resistant bacteria

Multi-omics approach identifies potential drug combinations for AML treatment

New approach to treating ependymoma with leukemia drug

Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients

Metronomic chemotherapy offers hope for children with neuroblastoma

Prehabilitation associated with fewer complications and improved recovery after surgery

Prehabilitation may improve surgical recovery and reduce complications

Real-world effectiveness and safety of olaparib in HRD-positive BRCA wild-type ovarian cancer

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Genomic insights and new treatment paradigms related to HER2-low breast cancer

New air-liquid interface method enhances hair follicle formation in skin organoids

Study identifies new molecular target for treating keloids

Diagnostic guidelines released for limbic-predominant age-related TDP-43 encephalopathy

Single dose of novel drug shows tumor-clearing potential in breast cancer models

Green tea enriched films show promise for treating oral mucositis

Antidepressant fluoxetine found ineffective for early COVID-19 treatment

How gut microbiota impacts childhood obesity

SHEA calls for continued U.S. partnership with the World Health Organization

Pregnant women often left out of drug trials, study finds

Azvudine beats paxlovid in reducing COVID-19 deaths

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News